All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @wellnessbyhaleigh on TikTok · 61s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @wellnessbyhaleigh's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00shot day.
  2. 0:06In my stomach.
  3. 0:09First things first, we're starting off with our alcohol pad.
  4. 0:15For those of you who are wondering what the needle looks like, this is the size of the needle. It needs to be
  5. 0:22so hot.
  6. 0:23And that is it. Shot days are always so easy. It's nothing to worry about.
  7. 0:28I do mine on Sundays and I just like it better because then it's like I have this entire week to really absorb everything.
  8. 0:37And my side effects, I never get bad side effects either.
  9. 0:40I like to do it right before I go to bed and then I can just sleep through the night.
  10. 0:44So is it busy?
  11. 0:46Women's crazy.
  12. 0:48Michael with my entire process now that I've lost all the weight is just our gaining muscle and really focusing on protein and
  13. 0:55feeling my body. Let me know if you have any questions. Bye.

@wellnessbyhaleigh's GLP-1 injection tips, fact-checked

Wellnessbyhaleigh

TikTok creator

74.7K viewsWatch on TikTok

Quick answer

Semaglutide is a once-weekly GLP-1 receptor agonist with a half-life of approximately 165-184 hours, making consistent weekly dosing a pharmacologically sound practice for maintaining stable plasma concentrations. The STEP 1 trial (Wilding et al., 2021, NEJM) demonstrated 14.9% mean body weight reduction over 68 weeks but also documented nausea in 44% and vomiting in 25% of participants, data that contrasts sharply with the creator's characterization of minimal side effects. Injection site rotation to the abdomen, thigh, or upper arm is consistent with FDA-approved labeling for subcutaneous GLP-1 therapies to reduce localized tissue reactions.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 9 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @wellnessbyhaleigh's GLP-1 injection tips, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

@wellnessbyhaleigh's GLP-1 injection tips, fact-checked should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@wellnessbyhaleigh's GLP-1 injection tips, fact-checked" from Wellnessbyhaleigh. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Semaglutide is a once-weekly GLP-1 receptor agonist with a half-life of approximately 165-184 hours, making consistent weekly dosing a pharmacologically sound practice for maintaining stable plasma concentrations.

The reason this review is not generic is the source wording and the canonical claim label "glp1 glp 1 shot day tips save for your next day 1 stay cons." In this clip, the useful excerpt is: "shot day." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Semaglutide's half-life is approximately 165-184 hours (Kapitza et al.
People who land here are usually comparing the GLP-1 social video fact-checks claim with [object Object].
The strongest next step is to compare the claim with FormBlends' GLP-1 social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Semaglutide is a once-weekly GLP-1 receptor agonist with a half-life of approximately 165-184 hours, making consistent weekly dosing a pharmacologically sound practice for maintaining stable plasma concentrations.

FormBlends verdict

GLP-1 social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Semaglutide is a once-weekly GLP-1 receptor agonist with a half-life of approximately 165-184 hours, making consistent weekly dosing a pharmacologically sound practice for maintaining stable plasma concentrations. The STEP 1 trial (Wilding et al., 2021, NEJM) demonstrated 14.9% mean body weight reduction over 68 weeks but also documented nausea in 44% and vomiting in 25% of participants, data that contrasts sharply with the creator's characterization of minimal side effects. Injection site rotation to the abdomen, thigh, or upper arm is consistent with FDA-approved labeling for subcutaneous GLP-1 therapies to reduce localized tissue reactions.
  • 44% of semaglutide users in the STEP 1 trial experienced nausea; the 'easy, nothing to worry about' framing does not reflect typical patient experience during dose titration.
  • Semaglutide's half-life is approximately 165-184 hours (Kapitza et al., 2015), which is why once-weekly dosing maintains stable drug levels, not any weekly 'absorption' window.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • 44% of semaglutide users in the STEP 1 trial experienced nausea; the 'easy, nothing to worry about' framing does not reflect typical patient experience during dose titration.
  • Semaglutide's half-life is approximately 165-184 hours (Kapitza et al., 2015), which is why once-weekly dosing maintains stable drug levels, not any weekly 'absorption' window.
  • Rotating injection sites between the abdomen, thigh, and upper arm is FDA-label guidance for Wegovy and Ozempic to prevent localized skin reactions.
  • Bedtime dosing as a nausea strategy is patient-reported, not protocol-established. If GI side effects are severe, the right call is talking to your prescriber, not adjusting timing alone.
  • Sharps disposal from GLP-1 auto-injectors is regulated in most U.S. states. Used pens should go into an FDA-cleared sharps container, not household trash.
  • Proper subcutaneous technique (skin pinch, correct angle, no post-injection rubbing) was absent from this video despite being medically relevant for injection site tolerability.
  • Personal weight loss testimonials are not clinical evidence. Individual outcomes on GLP-1 therapy vary significantly based on dose, adherence, diet, and baseline metabolic factors.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @wellnessbyhaleigh actually say?

The video is a casual, first-person walkthrough of a weekly GLP-1 injection routine. She says she doses in her stomach, uses an alcohol pad to prep, does her shot on Sundays, and takes it "right before I go to bed" so she can "sleep through the night." She also mentions she never gets bad side effects and that her current focus has shifted to building muscle and eating more protein now that she's lost weight.

The caption (which appears to be cut off) adds two structured tips: keeping a consistent weekly injection time for side effect management, and rotating injection sites between the stomach, thigh, and back of the arm to avoid irritation. The spoken content is anecdotal. The written caption leans more instructional. That distinction matters when you're evaluating what's actually being communicated to 74,000-plus viewers.

Does the science back this up?

On the core practices, yes, mostly. Site rotation and consistent weekly timing are both grounded in real pharmacology. Semaglutide has a half-life of approximately seven days, which is precisely why once-weekly dosing works, and inconsistent timing can create variability in plasma concentration. The bedtime dosing angle is less studied but not unreasonable.

Semaglutide's half-life of around 165-184 hours (Kapitza et al., 2015, Clinical Pharmacokinetics) means timing precision matters less than it does for, say, a daily medication. But consistent dosing windows help patients build reliable habits, which itself reduces missed doses. The injection site rotation advice is supported by subcutaneous injection best practices for insulin and analogous drugs. The FDA-approved prescribing information for Wegovy specifies rotating sites to reduce localized lipohypertrophy. The bedtime claim, that you can "sleep through" nausea, is not directly tested in clinical trials but aligns loosely with anecdotal reports in patient communities and the known timing of peak GLP-1 receptor activity.

What did they get wrong (or right)?

She got the fundamentals right. Alcohol wipe before injection, site rotation, consistent weekly timing: these are standard, appropriate practices. Credit where it's due.

What's missing is more concerning than what's wrong. Saying "shot days are always so easy, it's nothing to worry about" is not universally true, and broadcasting that to tens of thousands of people starting their first injection is potentially misleading. Clinical trial data for semaglutide (STEP 1 trial, Wilding et al., 2021, New England Journal of Medicine) shows that nausea affected 44% of participants and vomiting affected 25%. Telling a broad audience that side effects are essentially a non-issue because of personal experience undersells the real landscape of what new patients may encounter. Her experience is valid. Her experience is not the norm. There is also no mention of proper needle disposal, which is a public health issue, not a nitpick. Sharps waste from GLP-1 injections is regulated in most U.S. states.

What should you actually know?

Three things matter here if you're a GLP-1 patient watching content like this.

First, consistent weekly timing is genuinely useful, but the reason is habit formation and steady-state plasma levels, not some kind of weekly absorption window. The phrase "this entire week to really absorb everything" is vague in a way that could be misread as pharmacologically meaningful. The drug's half-life manages that automatically.

Second, bedtime dosing is a reasonable strategy for some people. A small patient-reported survey published in Obesity Medicine (Wharton et al., 2021) noted that timing adjustments were a common self-management strategy for GI side effects. But it is not a guaranteed fix, and if you're experiencing significant nausea or vomiting, that warrants a conversation with your prescriber, not a TikTok workaround.

Third, injection technique matters beyond just wiping with alcohol. Pinching the skin, injecting at the correct angle, and not rubbing the site afterward are all part of proper subcutaneous technique. None of this appeared in the video. For a platform giving injection advice to a large audience, that's a meaningful gap.

Bottom line

This video is well-intentioned and the core advice is not wrong. But anecdotal experience shared at scale becomes de facto medical guidance, and the "nothing to worry about" framing around side effects does a disservice to the significant percentage of patients who do struggle, especially in the early titration phase. Personal testimonials are not clinical data, and the two should not be conflated.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Wellnessbyhaleigh · TikTok creator

74.7K views on this video

GLP-1 Shot Day Tips! Save for your next day!! 1. Stay consistent with timing. • Try to take your shot at the same time of day each week. It helps with side effect management and building a routine.

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about 44% of semaglutide users in the step 1 trial experienced?

44% of semaglutide users in the STEP 1 trial experienced nausea; the 'easy, nothing to worry about' framing does not reflect typical patient experience during dose titration.

What does the video say about semaglutide's half-life?

Semaglutide's half-life is approximately 165-184 hours (Kapitza et al., 2015), which is why once-weekly dosing maintains stable drug levels, not any weekly 'absorption' window.

What does the video say about rotating injection sites between the abdomen, thigh,?

Rotating injection sites between the abdomen, thigh, and upper arm is FDA-label guidance for Wegovy and Ozempic to prevent localized skin reactions.

What does the video say about bedtime dosing as a nausea strategy?

Bedtime dosing as a nausea strategy is patient-reported, not protocol-established. If GI side effects are severe, the right call is talking to your prescriber, not adjusting timing alone.

What does the video say about sharps disposal from glp-1 auto-injectors?

Sharps disposal from GLP-1 auto-injectors is regulated in most U.S. states. Used pens should go into an FDA-cleared sharps container, not household trash.

What does the video say about proper subcutaneous technique (skin pinch, correct angle, no post-injection rubbing)?

Proper subcutaneous technique (skin pinch, correct angle, no post-injection rubbing) was absent from this video despite being medically relevant for injection site tolerability.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Wellnessbyhaleigh, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.